Please contact us for more information or to learn if you are eligible to participate.
To determine the effect of once-daily, oral administration of 80 or 100 mg MGL-3196 versus matching placebo on NASH
Principal Investigator | Fernando Membreno, MD |
Co-PI | John Rodriguez |
Sponsor | Madrigal Pharmaceuticals, Inc. |
Type of Trial | Interventional |